United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

United Therapeutics Corporation

Leerink Partners analyst Roanna Ruiz reiterated a Buy rating on United Therapeutics yesterday. The company’s shares closed yesterday at $476.86. Ru...

Leerink Partners Reaffirms Their Buy Rating on United Therapeutics (UTHR)

United Therapeutics Corp. ($UTHR) announced an update on their ongoing clinical study. Study Overview: United Therapeutics is running a phase 3 tri...

United Therapeutics’ Phase 3 Ralinepag Trial Reaches Completion, Setting Up a Key Catalyst in Pulmonary Arterial Hypertension

UBS analyst Ashwani Verma maintained a Buy rating on United Therapeutics today and set a price target of $645.00. Verma covers the Healthcare secto...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	UTHR	$477.44	+0.51%	156.22K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	UTHR	$477.44	+0.5%	156.22K
3
4
5
6

UTHR

UTHR

Latest News for UTHR

Get United Therapeutics Corporation Data in Excel

Get United Therapeutics Corporation Data in Excel